Pub Date : 2025-09-01DOI: 10.1016/j.dsx.2025.103305
Bethany L. Armentrout , Megan L. Wenzell , Kingman P. Strohl , Sybil L. Crawford , Jamie R. Wood , Chiang-shan R. Li , Ronald L. Hickman Jr. , Stephanie Alisha Griggs
Aims
To investigate the preliminary efficacy of a cognitive behavioral sleep and circadian intervention on glycemic and psychological outcomes in young adults with type 1 diabetes.
Methods
Glycemic and psychological outcomes were evaluated in 39 young adults (mean age 21.08, diabetes duration 11.7 years, mean glycated hemoglobin 8.46 %, 41 % female) from March 2022 to October 2023. Participants were randomly assigned (1:1) to a 12-week cognitive behavioral sleep and circadian condition (n = 21) or a time-balanced attention control condition (n = 18). Data were collected using continuous glucose monitors, research-grade actigraphy, and daily sleep surveys at baseline, post-intervention, and 3-month follow-up.
Results
The cognitive behavioral sleep and circadian intervention condition showed significant improvements in glycemic outcomes, with reductions in the coefficient of variation and mean amplitude of glucose excursions three months post-intervention. It also resulted in decreased diabetes distress at both time points, unlike the Attention Control group, which had minimal changes.
Conclusions
Future research should confirm these preliminary findings in larger, more diverse samples with varied intervention lengths and a longer-term follow-up.
{"title":"A randomized pilot sleep and circadian behavior clinical trial to improve glycemic and psychological outcomes in young adults with type 1 diabetes (NCT04975230)","authors":"Bethany L. Armentrout , Megan L. Wenzell , Kingman P. Strohl , Sybil L. Crawford , Jamie R. Wood , Chiang-shan R. Li , Ronald L. Hickman Jr. , Stephanie Alisha Griggs","doi":"10.1016/j.dsx.2025.103305","DOIUrl":"10.1016/j.dsx.2025.103305","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the preliminary efficacy of a cognitive behavioral sleep and circadian intervention on glycemic and psychological outcomes in young adults with type 1 diabetes.</div></div><div><h3>Methods</h3><div>Glycemic and psychological outcomes were evaluated in 39 young adults (mean age 21.08, diabetes duration 11.7 years, mean glycated hemoglobin 8.46 %, 41 % female) from March 2022 to October 2023. Participants were randomly assigned (1:1) to a 12-week cognitive behavioral sleep and circadian condition (n = 21) or a time-balanced attention control condition (n = 18). Data were collected using continuous glucose monitors, research-grade actigraphy, and daily sleep surveys at baseline, post-intervention, and 3-month follow-up.</div></div><div><h3>Results</h3><div>The cognitive behavioral sleep and circadian intervention condition showed significant improvements in glycemic outcomes, with reductions in the coefficient of variation and mean amplitude of glucose excursions three months post-intervention. It also resulted in decreased diabetes distress at both time points, unlike the Attention Control group, which had minimal changes.</div></div><div><h3>Conclusions</h3><div>Future research should confirm these preliminary findings in larger, more diverse samples with varied intervention lengths and a longer-term follow-up.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103305"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.dsx.2025.103302
Bernard Kwadwo Yeboah Asiamah-Asare , Sean Randall , George Mnatzaganian , Richard Varhol , Crystal Man Ying Lee , Kevin Chai , James Boyd , Gill Cowen , Sangita Shakya , Lan Gao , Suzanne Robinson
Background
Diabetes poses huge financial implications for individuals and healthcare systems. This study aims to quantify the incremental direct healthcare costs associated with diabetes in Australia.
Methods
This matched retrospective cohort study used a linked administrative dataset for Western Australia. Diabetes cases (n = 18,937) were matched 1:1 to controls based on age, sex, remoteness, and weight status. Direct healthcare costs incurred by the government, including costs of hospital admissions, emergency presentations, prescribed medications, general practice visits, and pathology tests, were estimated for 2021, with costs expressed in 2024 Australian Dollars (AUD). The incremental cost was calculated as the difference between the average annual costs of people with diabetes and those without diabetes, and the cost was extrapolated to the total population in 2024.
Results
Average annual healthcare costs per person with diabetes (AUD 9677) were 2.1 times higher than those without diabetes (AUD 4669). The average annual costs attributable to people with Type 2 Diabetes (AUD 5135) were higher than those with Type 1 Diabetes (AUD 4295). The incremental costs of diabetes (AUD 5008) significantly varied across age groups, remoteness, weight status, socioeconomic status and smoking status. In Australia, the total healthcare cost associated with diabetes in 2024 was estimated at AUD 14.2 billion, and the total incremental cost associated with diabetes was estimated at AUD 7.3 billion.
Conclusions
Diabetes imposes a substantial excess direct healthcare cost burden. Evidence could guide the planning and allocation of resources, as well as support the need for targeted health interventions.
{"title":"The economic impact of diabetes: Assessing incremental direct costs in Australia using linked administrative data","authors":"Bernard Kwadwo Yeboah Asiamah-Asare , Sean Randall , George Mnatzaganian , Richard Varhol , Crystal Man Ying Lee , Kevin Chai , James Boyd , Gill Cowen , Sangita Shakya , Lan Gao , Suzanne Robinson","doi":"10.1016/j.dsx.2025.103302","DOIUrl":"10.1016/j.dsx.2025.103302","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes poses huge financial implications for individuals and healthcare systems. This study aims to quantify the incremental direct healthcare costs associated with diabetes in Australia.</div></div><div><h3>Methods</h3><div>This matched retrospective cohort study used a linked administrative dataset for Western Australia. Diabetes cases (n = 18,937) were matched 1:1 to controls based on age, sex, remoteness, and weight status. Direct healthcare costs incurred by the government, including costs of hospital admissions, emergency presentations, prescribed medications, general practice visits, and pathology tests, were estimated for 2021, with costs expressed in 2024 Australian Dollars (AUD). The incremental cost was calculated as the difference between the average annual costs of people with diabetes and those without diabetes, and the cost was extrapolated to the total population in 2024.</div></div><div><h3>Results</h3><div>Average annual healthcare costs per person with diabetes (AUD 9677) were 2.1 times higher than those without diabetes (AUD 4669). The average annual costs attributable to people with Type 2 Diabetes (AUD 5135) were higher than those with Type 1 Diabetes (AUD 4295). The incremental costs of diabetes (AUD 5008) significantly varied across age groups, remoteness, weight status, socioeconomic status and smoking status. In Australia, the total healthcare cost associated with diabetes in 2024 was estimated at AUD 14.2 billion, and the total incremental cost associated with diabetes was estimated at AUD 7.3 billion.</div></div><div><h3>Conclusions</h3><div>Diabetes imposes a substantial excess direct healthcare cost burden. Evidence could guide the planning and allocation of resources, as well as support the need for targeted health interventions.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103302"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.dsx.2025.103312
José Seijas-Amigo , Ángel Salgado-Barreira , Rosana Castelo-Dominguez , María Teresa Pérez-Álvarez , Belén Ponce-Piñón , Marlén Fernández-Silva , Marta Rodríguez-Barreiro , Mercedes Pereira-Pía , Jose Manuel Iglesias-Moreno , Mar Gago-García , Raquel Montáns-García , Agustina Fernandez-Perez , Dolores Fraga-Gayoso , Montse Fernandez-Montenegro , Beatriz Riveiro-Barciela , Natalia Rilla-Villar , Begoña Cardeso-Paredes , Marta Ribeiro-Ferreiro , Diego Rodriguez-Penas , Alberto Cordero , José R. González-Juanatey
Aims
Patients with Type 2 diabetes mellitus face elevated cardiovascular risk. We assessed the effect of GLP-1 receptor agonists on 10-year CVR in a primary prevention cohort.
Methods
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers. The primary endpoint was the change in 10-year cardiovascular risk, estimated using the AHA ASCVD Risk Estimator Plus tool at baseline and week 44. Secondary endpoints included weight loss, HbA1c, fasting plasma glucose, and lipid profiles. Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
Results
In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001). Subcutaneous semaglutide showed the greatest weight loss (−8.1 kg), followed by oral semaglutide (−6.5 kg) and dulaglutide (−5.6 kg). HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
Conclusions
GLP-1 receptor agonists reduce 10-year cardiovascular risk in primary prevention and improve metabolic control. Findings support early use in high-risk people with type 2 diabetes.
{"title":"Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study","authors":"José Seijas-Amigo , Ángel Salgado-Barreira , Rosana Castelo-Dominguez , María Teresa Pérez-Álvarez , Belén Ponce-Piñón , Marlén Fernández-Silva , Marta Rodríguez-Barreiro , Mercedes Pereira-Pía , Jose Manuel Iglesias-Moreno , Mar Gago-García , Raquel Montáns-García , Agustina Fernandez-Perez , Dolores Fraga-Gayoso , Montse Fernandez-Montenegro , Beatriz Riveiro-Barciela , Natalia Rilla-Villar , Begoña Cardeso-Paredes , Marta Ribeiro-Ferreiro , Diego Rodriguez-Penas , Alberto Cordero , José R. González-Juanatey","doi":"10.1016/j.dsx.2025.103312","DOIUrl":"10.1016/j.dsx.2025.103312","url":null,"abstract":"<div><h3>Aims</h3><div>Patients with Type 2 diabetes mellitus face elevated cardiovascular risk. We assessed the effect of GLP-1 receptor agonists on 10-year CVR in a primary prevention cohort.</div></div><div><h3>Methods</h3><div>In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers. The primary endpoint was the change in 10-year cardiovascular risk, estimated using the AHA ASCVD Risk Estimator Plus tool at baseline and week 44. Secondary endpoints included weight loss, HbA1c, fasting plasma glucose, and lipid profiles. Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.</div></div><div><h3>Results</h3><div>In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001). Subcutaneous semaglutide showed the greatest weight loss (−8.1 kg), followed by oral semaglutide (−6.5 kg) and dulaglutide (−5.6 kg). HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).</div></div><div><h3>Conclusions</h3><div>GLP-1 receptor agonists reduce 10-year cardiovascular risk in primary prevention and improve metabolic control. Findings support early use in high-risk people with type 2 diabetes.</div></div><div><h3>Trial registration</h3><div><span><span>clinicaltrials.gov</span><svg><path></path></svg></span> Identifier: NCT05136287.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103312"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145357537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.dsx.2025.103314
Lindsay A. Courtney , Jennifer N. Clements , Diana Isaacs , Jamie M. Pitlick , Sara Mandy Reece , Heather P. Whitley
Aims
This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages.
Methods
The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics.
Results
There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration.
Conclusion
Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.
{"title":"Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy","authors":"Lindsay A. Courtney , Jennifer N. Clements , Diana Isaacs , Jamie M. Pitlick , Sara Mandy Reece , Heather P. Whitley","doi":"10.1016/j.dsx.2025.103314","DOIUrl":"10.1016/j.dsx.2025.103314","url":null,"abstract":"<div><h3>Aims</h3><div>This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages.</div></div><div><h3>Methods</h3><div>The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics.</div></div><div><h3>Results</h3><div>There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration.</div></div><div><h3>Conclusion</h3><div>Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103314"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.dsx.2025.103298
Stephan Peronard Mayntz , Roda Abdulkadir Mohamed , Anna Mejldal , Jens-Jakob Kjer Møller , Jes Sanddal Lindholt , Axel Cosmus Pyndt Diederichsen , Lise Marie Frohn , Jørgen Brandt , Matthias Ketzel , Jibran Khan , Jess Lambrechtsen
Aim
The global burden of type 2 diabetes (T2D) continues to rise, with evidence suggesting that air pollution may contribute to its pathogenesis. This study examines the association between long-term exposure to fine particulate matter (PM2.5) and the risk of developing T2D in a cohort of older Danish men living in a low-exposure setting.
Methods
We conducted a prospective cohort study using 16,665 participants from the Viborg Vascular (VIVA) screening trial, aged 65–74 years without T2D at baseline. Residential PM2.5 was modeled with the DEHM/UBM/AIRGIS system from historical address data; road-traffic noise was estimated with Nord2000. Cox models with age as timescale evaluated time-varying PM2.5 exposure and T2D risk, adjusting for age, BMI, smoking status, socioeconomic factors, and traffic noise exposure.
Results
Over a mean 9.3-year follow-up, 324 participants (1.9 %) developed T2D. Incidence was lower than reported in prevention trials, reflecting differences in population risk and registry-based outcome capture. Participants who developed T2D had slightly higher long-term PM2.5 exposure compared to non-cases (12.12 vs 11.93 μg/m3; p < 0.001). Although absolute differences in exposure were small, they were consistent across the exposure distribution, suggesting a population-level effect even in a low-pollution environment. In adjusted time-varying Cox models, a 1.15 μg/m3 increment in PM2.5 was associated with a 30.6 % higher risk of T2D (HR 1.306, 95 % CI 1.08–1.58; p = 0.006). Associations were independent of body mass index, smoking, socioeconomic status, and traffic noise.
Conclusions
Long-term PM2.5 exposure was associated with T2D incidence in this cohort of older Danish men. Findings are hypothesis-generating, most applicable to low-to-moderate exposure settings, and should be interpreted with caution.
全球2型糖尿病（T2D）负担持续上升，有证据表明空气污染可能与其发病机制有关。本研究调查了长期暴露于细颗粒物（PM2.5）与低暴露环境中丹麦老年男性患T2D风险之间的关系。方法：我们对来自Viborg血管（VIVA）筛查试验的16,665名参与者进行了一项前瞻性队列研究，这些参与者年龄在65-74岁之间，基线时无T2D。利用DEHM/UBM/AIRGIS系统对历史地址数据进行住区PM2.5建模；道路交通噪音是用Nord2000估计的。以年龄为时间尺度的Cox模型评估了随时间变化的PM2.5暴露和T2D风险，调整了年龄、BMI、吸烟状况、社会经济因素和交通噪声暴露。结果在平均9.3年的随访中，324名参与者（1.9%）发生了T2D。发病率低于预防试验报告，反映了人群风险和基于登记的结果捕获的差异。患T2D的参与者与未患T2D的参与者相比，长期暴露在PM2.5中的比例略高（12.12 vs 11.93 μg/m3; p < 0.001）。虽然暴露的绝对差异很小，但它们在暴露分布中是一致的，这表明即使在低污染环境中也存在人群水平的影响。在调整后的时变Cox模型中，PM2.5浓度每增加1.15 μg/m3， T2D风险增加30.6% （HR 1.306, 95% CI 1.08-1.58; p = 0.006）。相关性与体重指数、吸烟、社会经济地位和交通噪音无关。结论：长期暴露于PM2.5与丹麦老年男性T2D发病率相关。研究结果是假设产生的，最适用于低至中等暴露环境，应谨慎解释。
{"title":"Association between long-term fine particulate matter exposure and incident type 2 diabetes in a low-exposure Danish cohort: An AIRCARD analysis","authors":"Stephan Peronard Mayntz , Roda Abdulkadir Mohamed , Anna Mejldal , Jens-Jakob Kjer Møller , Jes Sanddal Lindholt , Axel Cosmus Pyndt Diederichsen , Lise Marie Frohn , Jørgen Brandt , Matthias Ketzel , Jibran Khan , Jess Lambrechtsen","doi":"10.1016/j.dsx.2025.103298","DOIUrl":"10.1016/j.dsx.2025.103298","url":null,"abstract":"<div><h3>Aim</h3><div>The global burden of type 2 diabetes (T2D) continues to rise, with evidence suggesting that air pollution may contribute to its pathogenesis. This study examines the association between long-term exposure to fine particulate matter (PM<sub>2.5</sub>) and the risk of developing T2D in a cohort of older Danish men living in a low-exposure setting.</div></div><div><h3>Methods</h3><div>We conducted a prospective cohort study using 16,665 participants from the Viborg Vascular (VIVA) screening trial, aged 65–74 years without T2D at baseline. Residential PM<sub>2.5</sub> was modeled with the DEHM/UBM/AIRGIS system from historical address data; road-traffic noise was estimated with Nord2000. Cox models with age as timescale evaluated time-varying PM<sub>2.5</sub> exposure and T2D risk, adjusting for age, BMI, smoking status, socioeconomic factors, and traffic noise exposure.</div></div><div><h3>Results</h3><div>Over a mean 9.3-year follow-up, 324 participants (1.9 %) developed T2D. Incidence was lower than reported in prevention trials, reflecting differences in population risk and registry-based outcome capture. Participants who developed T2D had slightly higher long-term PM<sub>2.5</sub> exposure compared to non-cases (12.12 vs 11.93 μg/m<sup>3</sup>; p < 0.001). Although absolute differences in exposure were small, they were consistent across the exposure distribution, suggesting a population-level effect even in a low-pollution environment. In adjusted time-varying Cox models, a 1.15 μg/m<sup>3</sup> increment in PM<sub>2.5</sub> was associated with a 30.6 % higher risk of T2D (HR 1.306, 95 % CI 1.08–1.58; p = 0.006). Associations were independent of body mass index, smoking, socioeconomic status, and traffic noise.</div></div><div><h3>Conclusions</h3><div>Long-term PM<sub>2.5</sub> exposure was associated with T2D incidence in this cohort of older Danish men. Findings are hypothesis-generating, most applicable to low-to-moderate exposure settings, and should be interpreted with caution.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 8","pages":"Article 103298"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145099509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.dsx.2025.103296
Chang Liu , Hao Wang , Lin Hua , Zhong Xin
Introduction
Despite rising global health concerns about sugar-sweetened beverages (SSBs), their long-term impact on non-communicable disease (NCD) death across demographic groups and socioeconomic contexts remains poorly understood.
Methods
We analyzed SSB-attributable NCD death trends using the Global Burden of Disease (GBD) Study 2021 data from 204 countries (1990–2021). Time trends in death were expressed as average annual percent change (AAPC), stratified by age and socio-demographic index (SDI). Future trends through 2051 were projected using Bayesian age-period-cohort modeling.
Results
SSB-attributable deaths increased from 27,286 (95 % UI: 11,099–42,134) in 1990 to 74,657 (95 % UI: 33,724–115,575) in 2021. The age-standardized death rate rose from 0.784 to 0.889 per 100,000 (AAPC: 0.460 %, 95 % CI: 0.326–0.594). Young and middle-aged adults exhibited a rapid increase in deaths, with an AAPC of 1.250 % (95 % CI: 1.070–1.420) observed in the 25–29 age group, particularly due to chronic kidney disease (AAPC: 2.779 %, 95 % CI: 2.626–2.931). Low-middle SDI regions experienced the most dramatic increase (AAPC: 2.569 %, 95 % CI: 2.453–2.684).
Conclusion
Our findings reveal an alarming rise in SSB-attributable NCD deaths, particularly affecting young adults and resource-limited regions. This growing health equity challenge requires urgent policy interventions and prevention strategies to protect vulnerable populations.
{"title":"The growing deaths from non-communicable diseases attributable to sugar-sweetened beverages among young and middle-aged adults: Analysis and projection based on Global Burden of Disease Study 2021","authors":"Chang Liu , Hao Wang , Lin Hua , Zhong Xin","doi":"10.1016/j.dsx.2025.103296","DOIUrl":"10.1016/j.dsx.2025.103296","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite rising global health concerns about sugar-sweetened beverages (SSBs), their long-term impact on non-communicable disease (NCD) death across demographic groups and socioeconomic contexts remains poorly understood.</div></div><div><h3>Methods</h3><div>We analyzed SSB-attributable NCD death trends using the Global Burden of Disease (GBD) Study 2021 data from 204 countries (1990–2021). Time trends in death were expressed as average annual percent change (AAPC), stratified by age and socio-demographic index (SDI). Future trends through 2051 were projected using Bayesian age-period-cohort modeling.</div></div><div><h3>Results</h3><div>SSB-attributable deaths increased from 27,286 (95 % UI: 11,099–42,134) in 1990 to 74,657 (95 % UI: 33,724–115,575) in 2021. The age-standardized death rate rose from 0.784 to 0.889 per 100,000 (AAPC: 0.460 %, 95 % CI: 0.326–0.594). Young and middle-aged adults exhibited a rapid increase in deaths, with an AAPC of 1.250 % (95 % CI: 1.070–1.420) observed in the 25–29 age group, particularly due to chronic kidney disease (AAPC: 2.779 %, 95 % CI: 2.626–2.931). Low-middle SDI regions experienced the most dramatic increase (AAPC: 2.569 %, 95 % CI: 2.453–2.684).</div></div><div><h3>Conclusion</h3><div>Our findings reveal an alarming rise in SSB-attributable NCD deaths, particularly affecting young adults and resource-limited regions. This growing health equity challenge requires urgent policy interventions and prevention strategies to protect vulnerable populations.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 8","pages":"Article 103296"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.dsx.2025.103301
Anoop Misra , Sushum Sharma
{"title":"BMI lower than 23 kg/m2 is better for screening of diabetes and cardiovascular risk in Asian Indians?: Clinical and research implications of emerging data","authors":"Anoop Misra , Sushum Sharma","doi":"10.1016/j.dsx.2025.103301","DOIUrl":"10.1016/j.dsx.2025.103301","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 8","pages":"Article 103301"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.dsx.2025.103300
Abhinav Kanwal , Navjot Kanwar , Maya P. Shetty , Komal Rana , Anna Alisi , Amit Bhatia , Sanjay Bharati
Background
Cell junctions play a pivotal role in the normal functioning of tissues. The alterations in the expression or structure of these junctions are linked to several pathologies including diabetes mellitus and its secondary complications. Therefore, this review discusses the implications of diabetes mellitus on cell junctions across different organs and tissues.
Methodology
A systematic review of PubMed and other relevant search sources was conducted using relevant keywords in accordance with PRISMA guidelines. In addition, the reference lists of all included full texts were meticulously reviewed to find additional reports.
Results
Among 646 initially identified articles, 323 were found relevant and have been included in this review. The findings of the review suggested that hyperglycemia induces hyperphosphorylation of cell junctional proteins leading to mis-localization, downregulation and impaired intracellular communication. Although multiple junctions are affected, connexin-based gap junctions appear to be consistently affected across various tissues. This highlights their potential as a therapeutic target for mitigating diabetes mellitus and its associated complications.
Conclusions
Overall, this review highlights the types of cell junctions affected in diabetes mellitus across different tissues. Moreover, integration of cell junction-targeted interventions along with standard glycemic control regimens might provide synergistic benefits to prevent secondary diabetic complications.
{"title":"Impact of diabetes on cellular connections: Pathological insights and emerging therapeutic targets","authors":"Abhinav Kanwal , Navjot Kanwar , Maya P. Shetty , Komal Rana , Anna Alisi , Amit Bhatia , Sanjay Bharati","doi":"10.1016/j.dsx.2025.103300","DOIUrl":"10.1016/j.dsx.2025.103300","url":null,"abstract":"<div><h3>Background</h3><div>Cell junctions play a pivotal role in the normal functioning of tissues. The alterations in the expression or structure of these junctions are linked to several pathologies including diabetes mellitus and its secondary complications. Therefore, this review discusses the implications of diabetes mellitus on cell junctions across different organs and tissues.</div></div><div><h3>Methodology</h3><div>A systematic review of PubMed and other relevant search sources was conducted using relevant keywords in accordance with PRISMA guidelines. In addition, the reference lists of all included full texts were meticulously reviewed to find additional reports.</div></div><div><h3>Results</h3><div>Among 646 initially identified articles, 323 were found relevant and have been included in this review. The findings of the review suggested that hyperglycemia induces hyperphosphorylation of cell junctional proteins leading to mis-localization, downregulation and impaired intracellular communication. Although multiple junctions are affected, connexin-based gap junctions appear to be consistently affected across various tissues. This highlights their potential as a therapeutic target for mitigating diabetes mellitus and its associated complications.</div></div><div><h3>Conclusions</h3><div>Overall, this review highlights the types of cell junctions affected in diabetes mellitus across different tissues. Moreover, integration of cell junction-targeted interventions along with standard glycemic control regimens might provide synergistic benefits to prevent secondary diabetic complications.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 8","pages":"Article 103300"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.dsx.2025.103304
Ningjian Wang , Anoop Misra
{"title":"Highlights of the current issue","authors":"Ningjian Wang , Anoop Misra","doi":"10.1016/j.dsx.2025.103304","DOIUrl":"10.1016/j.dsx.2025.103304","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 8","pages":"Article 103304"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号